• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cureus . COVID-19 Associated Coagulopathy in the Setting of Underlying Malignancy

tetano

Editor, Senior Moderator
Cureus


. 2020 Aug 28;12(8):e10095.
doi: 10.7759/cureus.10095.
COVID-19 Associated Coagulopathy in the Setting of Underlying Malignancy


Su Lin Lim[SUP] 1 [/SUP], Kok Hoe Chan[SUP] 1 [/SUP], Jihad Slim[SUP] 2 [/SUP], Gunwant Guron[SUP] 3 [/SUP], Hamid S Shaaban[SUP] 3 [/SUP]



Affiliations

Abstract

Coronavirus disease 2019 (COVID-19) associated coagulopathy is a well-recognized predictor for morbidity and mortality in COVID-19 patients. Both deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in COVID-19 patients. Nonetheless, there are no consensus guidelines on the use of therapeutic coagulation in this group of patients. We herein present a unique case of a confirmed COVID-19 patient with metastatic ovarian cancer who presented with DVT and PE despite being on therapeutic anticoagulation, highlighting the unpredictability of COVID-19 associated coagulopathy. This case study raises the awareness that the thrombophilic state in metastatic malignancies is potentially augmented by COVID-19. We also discuss the complexity of making anticoagulation treatment decision in COVID-19 patients in the absence of evidence-based guidelines.

Keywords: covid-19 associated coagulopathy; deep venous thrombosis; metastatic ovarian cancer; pulmonary embolism.
 
Back
Top Bottom